


# Molecular Docking in the Cloud: Introduction to Molecular Docking

PhD. Pablo Ricardo Arantes  
PhD. Conrado Pedebos

Porto Alegre, July 14<sup>th</sup> 2025

# Drug Discovery Cycle




# Drug Discovery Cycle




# Drug Discovery Cycle - Virtual Screening

- Rapidly screen large libraries of small molecules (e.g., millions of compounds) to identify "hits" that bind to a target protein (e.g., an enzyme or receptor involved in a disease).
- Cost-effective alternative to High-Throughput Screening (HTS)
- Part of iterative **Design–Make–Test–Analyze** loop
- **Main types:** Structure-Based (SBVS) and Ligand-Based (LBVS)
- **Advantage:** Reduces wet-lab screening costs by focusing on computationally selected candidates.



# Virtual Screening



# Virtual Screening

Requires 3D structure of the target


**Steps:**

- Receptor & ligand preparation
- Docking using a scoring function
- Post-processing & hit selection

B

## Structure-based virtual screening


- 1 Structure-based pharmacophore modeling
- 2 Molecular dynamics simulation
- 3 Molecular docking



**Molecular Dynamics** plays a dual role (receptor - first step / complex - final step)

## Ligand-based virtual screening

- 1 Ligand-based pharmacophore modeling
- 2 Machine learning algorithms
- 3 3D shape similarity search
- 4 Molecular fingerprints



Used when target structure is unknown. Relies on known actives to find similar compounds


**Methods:**

- 2D/3D similarity searches
- Pharmacophore modeling
- Machine learning classifiers

# Virtual Screening - Ligand-Based

- Pharmacophore-based VS



**Pharmacophore** = a set of steric and electronic characteristics required to ensure better interactions with a particular biological target





# Virtual Screening - Ligand-Based



- Machine Learning approaches






# Virtual Screening - Ligand-Based


- Fingerprints:
  - Mathematical or vectorial representations = chemical and structural representations of a molecule
  - Similarity between molecules (Tanimoto more common)
  - Scalable, fast to calculate and compare, dimensionality reduction



# Virtual Screening - Structure-Based



# Virtual Screening - Structure-Based



Protein  
and ligand  
selection

- Structure of the protein target (3D coordinates)
- 3D coordinates of ligand(s)

Receptor Structure



## AlphaFold

Accelerating breakthroughs in biology with AI

[Explore the AlphaFold Database >](#)

## Modeller

Program for Comparative Protein  
Structure Modelling by Satisfaction  
of Spatial Restraints

Compound Library



Compound Library (Natural Products)

SuperNatural 3.0




COCONUT

Latin American Natural Product Database (LANaPDB)

# Virtual Screening - Structure-Based

Ligand preparation




- Add hydrogens
- Check protonation state(s)
- Select proper tautomer/protomer /stereoisomer

- Experimentally (3D structure of protein-ligand complex is available)
- Cavity detection



Ligand-binding site prediction based on machine learning.



Protein preparation

**PDBFixer**

<https://github.com/openmm/pdbfixer>




# Virtual Screening - Compound Filtering

- Property-based filtering - A set of conditions that must be met by a compound to be used in the screening

	MW (Da)	PSA (Å <sup>2</sup> )	HBA	HBD	cLogP/cLogD	RTB	NAR	Formal charge	References
Lipinski's rule (RO5)	≤500	–	0–10	0–5	≤5	–	–	–	Lipinski et al., 1997
Ghose's rule	160–480	–	–	–	–0.4 to +5.6	–	20–70	–	Ghose et al., 1999
Oprea's drug-like rule	–	–	2–9	0–2	–	2–8	–	–	Oprea, 2000
Walters	200–500	≤120	0–10	0–5	–	0–8	–	–	Walters and Murcko, 2002
Veber's rule	–	≤140	–	–	–	0–10	–	–	Veber et al., 2002
REOS	200–500	–		0–5	–5.0 to 5.0	0–8		–2 to +2	Walters and Namchuk, 2003
Beyond rule of five (bRO5)	≤1,000	<250	<15	≤6	–2 to 10	≤20	–	–	Doak et al., 2014
Congreve's rule (RO3)	<300	–	≤6	≤3	≤3	–	–	–	Congreve et al., 2003
Herbicide-likeness	150–500	–	2–12	<3	≤3.5	<12	–	–	Tice, 2001
Insecticide-likeness	150–500	–	1–18	≤2	0–5	<12	–	–	Tice, 2001
Hao's rule (pesticide-likeness)	≤435	–	≤6	≤2	≤6	≤9	≤17	–	Hao et al., 2011

MW, molecular weight; PSA, polar surface area; HBD, hydrogen bond donor; HBA, hydrogen bond acceptor; RTB, rotatable bonds; NAR, number of aromatic rings.

# Virtual Screening - Structure-Based




## GNINA Docking

<https://github.com/gnina/gnina>




<https://github.com/dptech-corp/Uni-Dock>





# Virtual Screening - Structure-Based





**GNINA Docking**

<https://github.com/gnina/gnina>



<https://github.com/dptech-corp/Uni-Dock>



**Molecular  
docking**


**Evaluation**

- Exploring the conformational space (searching algorithm)
- Ranking candidate solutions (scoring function)

- Are all the H-bond donors and acceptors in the ligand satisfied?
- If the complex is known, is the binding mode of a ligand to protein reproduced?



# Virtual Screening - Structure-Based



**GNINA Docking**


<https://github.com/gnina/gnina>




<https://github.com/dptech-corp/Uni-Dock>



10.000 molecules in <42 hours  
1.000.000 molecules in 173 days :(



# Virtual Screening - Structure-Based



**GNINA Docking**


<https://github.com/gnina/gnina>




<https://github.com/dptech-corp/Uni-Dock>



10.000 molecules in <42 hours  
1.000.000 molecules in 173 days :(



# Virtual Screening - Structure-Based



**GNINA Docking**


<https://github.com/gnina/gnina>



<https://github.com/dptech-corp/Uni-Dock>







**10.000 molecules in less than 1.5 hour**  
**1.000.000 molecules in less than 6 days!!!**



# Virtual Screening - Structure-Based

- Evaluation
  - Clusters
  - Molecule ranking (scoring methods)

Product of pose  
classification and  
predicted binding  
affinity



	Molecule_Solution	minimizedAffinity	CNNscore	CNNaffinity	CNN_VS
0	mol_6087_1	-7.93925	0.911983	6.780704	6.183887
1	mol_5986_1	-8.11932	0.915682	6.498751	5.950791
2	mol_1600_1	-7.45823	0.881309	6.533484	5.758017
3	mol_3631_1	-7.96031	0.909520	6.195273	5.634723
4	mol_193_1	-8.73742	0.917535	6.130170	5.624646
...	...	...	...	...	...
62675	mol_1514_8	-6.83488	0.110981	3.370108	0.374019
62676	mol_2437_9	-6.42252	0.100460	3.688916	0.370587
62677	mol_771_9	-5.51312	0.130097	2.767925	0.360099
62678	mol_771_10	-5.47916	0.121043	2.877078	0.348249
62679	mol_2437_10	-6.92232	0.100410	3.424139	0.343818

# Virtual Screening - Post-processing

- What's next?
  - Redo the VS using different conformations of the same receptor
    - Copies of the same receptor from the RCSB PDB
    - Ensemble obtained from Molecular Dynamics simulations
  - Molecular Dynamics to refine the top poses
  - Other binding energy predictors
    - MM-PBSA (frames from the MD simulations) - shown to greatly reduce the rate of false positives
    - AEV-PLIG
  - PLACER
  - **Visual Inspection by a medicinal chemist**
    - Reliable interactions?
    - Synthetic feasibility
    - Intellectual Property?
  - **Predictions of ADMETox properties**

# Virtual Screening - Post-processing



SwissSimilarity  
SwissDrugDesign

[Home](#) [About](#) [FAQ](#) [Tutorials](#) [Command-line](#) [Citing](#) [Contact](#)

Don't know where to start? Try with an example **Diclofenac**, **Propranolol** or **Nilotinib**.

1 - Enter a molecule in SMILES format

No SMILES available? Draw a molecule **using the sketcher**

2 - Select a class of compounds

Please, select a class of compounds here:

3 - Select compound library and screening method

Put the mouse over a radio button to see the corresponding computation time

2D							3D	2D & 3D	
<input type="radio"/> FP2	<input type="radio"/> ECPA	<input type="radio"/> MHPP6	<input type="radio"/> Pharmacophore	<input type="radio"/> ErG	<input type="radio"/> Scaffold	<input type="radio"/> Generic Scaffold	<input type="radio"/> Electroshape	<input type="radio"/> E3P	<input type="radio"/> Combined

4 - Submit

START SCREENING


Reset form

# Virtual Screening - Post-processing



[Home](#) [About](#) [FAQ](#) [Help](#) [Citing](#) [Contact](#) [Terms of Use](#)

**For information:** We have changed the look and feel of our tool. However, we have **NOT** changed the underlying technologies and parameters. Consequently, this updated Web tool provides exactly the same results as the previous version.



Enter a list of SMILES here:

C0c1cc(0)c2c(c1)CCc1cc(0)ccc1-2

[Fill with an example](#)

[Clear](#)

[Run!](#)



# Virtual Screening - Post-processing

**Arom.:** if high, might be less soluble

**Fraction Csp3:** sp3 carbons; values > 0.3 indicate more complex structures (higher drug likeness); low values -> planar structures.


**Rot. bonds:** ideal < 10 (Veber), if >, less oral bioavail.

**HBA:** ideal <10; **HBD:** <5

**Molar Refrac.:** 40-130 (Ghose); too low = low affinity; too high = low solub.

**TPSA:** ideal < 140 for oral absorp.; < 90 cross BBB

**Ideally:** -0.5 a 5.0 (Lipinski). < -1: too hydrophilic; > 5: risk having low solubility and high toxicity.



**Water solub:** ideal > -4.0 and < 0.5 for oral absorp.

**Pharmacok:**

GI abs. = oral absorp.

BBB = good for SNC drugs, bad for side-effects

P-gp = if Yes, might have less bioavail. and tissue accum.

CYP inh. = relevant for drug-drug interact.

Log K<sub>p</sub> = -4 to -8 typically (more -, more perm.)

# Virtual Screening - Post-processing

**SwissBioisostere**  
SwissDrugDesign

Home About FAQ Help Tutorials Citing Contact [old.swissbioisostere.ch](http://old.swissbioisostere.ch)

I want to search for possible replacements of a fragment

I want to get information on a given molecular replacement

**Fragment 1**



Marvin JS  
by ChemAxon

SMILES:

 E-mail (optional):

Fill with an example: [side chain](#), [linker](#), [scaffold](#)